

NanOlogy has transformed systemic chemotherapy into local delivery directly to the site of disease to enhance tumor kill and resulting immune response.

HIGHLIGHTS

Innovative approach

Our technology forms submicron particles of paclitaxel and docetaxel without the need for coating or carrier agents designed for local delivery to the site of disease.

Two modes of tumor activity

1. Prolonged direct tumor kill
2. Immune-mediated tumor kill

Minimal side effects

Minimal systemic side effects observed across multiple clinical trials.

Extensive pipeline

An extensive preclinical and clinical pipeline in genitourinary, gastrointestinal, peritoneal, lung, and skin cancers.

Overview

NanOlogy is a clinical stage oncology company formed to advance a proprietary submicron particle production technology for treatment of cancer.

Designed for local delivery, patented submicron particles of pure drug are delivered directly to the site of disease via direct injection, inhalation, or topical application in high concentration where the particles release active drug over time.

Preclinical and clinical data across broad therapeutic areas including genitourinary, gastrointestinal, peritoneal, and lung cancers indicate enhanced tumor kill, significant immune stimulation, and minimal systemic side effects.



NanOlogy Value Proposition



Therapeutic Potential for Both Early and Late Disease



Broad Therapeutic Applications



De-risked Regulatory Pathway



Extensive Global IP Portfolio

Promising Preclinical/Clinical Data

NanoPac® Sterile Suspension	Evidence of activity in prostate and pancreas clinical trials Minimal drug-related adverse events Gradual drug clearance at subtoxic levels
NanoPac® Topical	Evidence of lesion reduction in AK and cutaneous metastases trials No local irritation and negligible systemic absorption following topical application
NanoDoce® Sterile Suspension	Sustained tumor reduction or eradication across multiple tumor types in preclinical studies Clinical trials in bladder and renal cancers to begin in 2019
NanoPac® Nebulized Inhalation	Preclinical studies show evidence of tumor regression and drug retention in lungs greater than 14 days IND-enabling toxicology studies underway
Immune Stimulation	Increased immune response in preclinical lung, renal, bladder, and breast models observed with targeted delivery Lymphocytic infiltration observed in prostate clinical trial Preclinical studies underway in syngeneic model and humanized model with IO combination

Development Pipeline

Investigational products in preclinical or clinical development

Therapeutic Area	Product	Indication	Delivery	Preclinical	Phase 1	Phase 2	Phase 3
Ovarian Cancer/ Peritoneal Malignancies	NanoPac® for Suspension Sterile Submicron Particle Paclitaxel	Ovarian Cancer	Intraperitoneal	→	→	→	
Gastrointestinal Oncology		Pancreatic Cancer	Intratumoral	→	→	→	
		Pancreatic Cyst	Intracystic	→	→	→	
Genitourinary		NanoDoce® for Suspension Sterile Submicron Particle Docetaxel	Prostate Cancer	Intratumoral	→	→	→
	Renal Cancer		Intratumoral	→			
Non-Small Cell Lung Cancer	NanoPac® for Nebulized Inhalation Submicron Particle Paclitaxel	Bladder Cancer	Direct Injection Intravesical Instillation	→			
		Non-Small Cell Lung Cancer	Nebulized Inhalation	→			
Dermal Oncology	NanoPac® Topical (SOR007) Ointment Submicron Particle Paclitaxel Ointment	Cutaneous Metastases	Topical	→	→	→	
		Actinic Keratosis	Topical	→	→	→	→ NanOlogy

NanOlogy Management Team

H. Paul Dorman, Chairman & CEO
Gere diZerega, MD, Chief Medical Officer
Mark Mitchell, Chief Legal Officer
Maxwell Lea, Managing Director
Marc Iacobucci, Managing Director

NanOlogy Advisor

Maurie Markman, MD, MS, FACP, FASCO,
 President, Medicine & Science,
 Cancer Treatment Centers of America®

Abstract Presentations

Lung Preclinical Data
 ASCO June 2018
Cutaneous Metastases
 SABCS December 2018
Genitourinary Preclinical Data
 ASCO-GU February 2019
Lung Preclinical Data
 ATS May 2019



Marc Iacobucci - marc.iacobucci@dfb.com; +817-916-2247
 Maxwell Lea - maxwell.lea@dfb.com; +817-900-4084
 NanOlogy, LLC 3909 Hulen Street, Fort Worth, TX 76107 USA
 www.nanology.us